Physician profile
Jane Ailene Daniel
NPI 1508842196
$2,734.93
in general payments reported to CMS, 2019-2025
25 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $409 · 2021: $865 · 2022: $405 · 2023: $265 · 2024: $199 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $432 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $432.48 |
| Education | $189.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,282.52 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $214.73 | 2023-2025 | Veozah |
| Pfizer INC. | $201.85 | 2020-2023 | |
| Exeltis, USA INC. | $179.74 | 2020-2025 | Slynd |
| Therapeuticsmd, INC. | $96.21 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $91.81 | 2019-2024 | Gardasil 9, Gardasil |
| Medtronic, INC. | $74.15 | 2021 | |
| Lupin INC. | $66.23 | 2019-2021 | |
| Organon LLC | $63.82 | 2022-2025 | Nexplanon |
| Myovant Sciences INC. | $58.04 | 2021-2022 | |
| Amgen INC. | $57.48 | 2021-2025 | Evenity |
| Evofem Biosciences, INC. | $54.36 | 2021-2022 | |
| Exact Sciences Corporation | $39.42 | 2023-2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $38.93 | 2023-2024 | Myfembree |
| Millicent US INC | $30.16 | 2020-2024 | Intrarosa, Femring |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $27.90 | 2020 | |
| Daiichi Sankyo INC. | $27.26 | 2020-2023 | Injectafer |
| Mayne Pharma Commercial LLC | $26.28 | 2021-2022 | |
| Zyla Life Sciences, INC. | $24.39 | 2020 | |
| Amag Pharmaceuticals, INC. | $23.48 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.03 | 2025 | |
| Avion Pharmaceuticals | $11.49 | 2020 | |
| Allergan, INC. | $11.34 | 2019 | |
| Duchesnay USA Incorporated | $11.31 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.